Concord Biotech invests USD 1,500 in Stellon Biotech Inc.

Concord Biotech Limited (BSE: CONCORDBIO) announced that it has made an equity investment of USD 1,500 in Stellon Biotech Inc., a Delaware-incorporated pharmaceutical company established in December 2024. The investment represents the subscription of 15 million equity shares at a price of USD 0.0001 per share, resulting in a 75% ownership stake. This acquisition is intended to support the marketing and commercialization of Concord Biotech's products in the United States. Stellon Biotech, currently in its pre-revenue phase, will manage operational functions including warehousing, inventory planning, and customer service while adhering to regulatory and compliance standards. The equity shares against this investment will be allotted within 90 days.